The molecular and ionic specificity of antiarrhythmic drug actions

Journal of Cardiovascular Electrophysiology

Volumn 10, Issue 2, 1999, Pages 272-282

  Nattel, Stanley ^a,b  

^a MONTREAL HEART INSTITUTE   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Calcium channels; Cardiac arrhythmias; Cardiac ion channels; Long QT syndrome; Potassium channels; Sodium channels

Indexed keywords

1 [2 (6 METHYL 2 PYRIDYL)ETHYL] 4 (4 METHYLSULFONYLAMINOBENZOYL)PIPERIDINE; ALMOKALANT; ANTIARRHYTHMIC AGENT; AZIMILIDE; CALCIUM CHANNEL; DOFETILIDE; ENCAINIDE; FLECAINIDE; IBUTILIDE; POTASSIUM CHANNEL; SEMATILIDE; SODIUM CHANNEL; SOTALOL;

ANTIARRHYTHMIC ACTIVITY; ATRIOVENTRICULAR CONDUCTION; CHLORIDE CURRENT; DOG; DRUG TARGETING; HEART ARRHYTHMIA; HEART INFARCTION; HEART MUSCLE POTENTIAL; HEART MUSCLE REFRACTORY PERIOD; HEART REPOLARIZATION; HEART SUPRAVENTRICULAR ARRHYTHMIA; HUMAN; ION CONDUCTANCE; LONG QT SYNDROME; NONHUMAN; POTASSIUM CURRENT; PRIORITY JOURNAL; REENTRY TACHYCARDIA; REVIEW; TORSADE DES POINTES;

EID: 0033011341     PISSN: 10453873     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1540-8167.1999.tb00673.x     Document Type: Review

References (75)

1. + current similar to Kv1.5 cloned channel currents. Circ Res 1993;73:1061-1076.
2. + current in human ventricular myocytes. Circ Res 1996;78:689-696.
3. + in single cardiac Purkinje cells. Am J Physiol 1989;257:C1086-C1092.
4. Kleiman RB, Houser SR: Outward currents in normal and hypertrophied feline ventricular myocytes. Am J Physiol 1989;256:H1450-H1461.
5. Yue L, Feng J, Li GR, et al: Characterization of an ultrarapid delayed rectifier potassium channel involved in canine atrial repolarization. J Physiol (Lond) 1996; 496:647-662.
6. Ks. Am J Physiol 1996;271(Pt 2):H2477-H2489.
7. Zygmunt AC, Gibbons WR: Properties of the calcium - activated chloride current in the heart. J Gen Physiol 1992;99:391-414.
8. + current by dofetilide. Circ Res 1993;72:75-83.
9. Hondeghem LM, Katzung BG: Antiarrhythmic agents: The modulated receptor mechanism of action of sodium and calcium channel-blocking drugs. Annu Rev Pharmacol Toxicol 1984;24:387-423.
10. Nattel S, Pedersen DH, Zipes DP: Alterations in regional myocardial distribution and arrhythmogenic effects of aprindine produced by coronary artery occlusion in the dog. Cardiovasc Res 1981;15:80-85.
11. Carson DL, Cardinal R, Savard P, et al: Relationship between an arrhythmogenic action of lidocaine and its effects on excitation patterns in acutely ischemic porcine myocardium. J Cardiovasc Pharmacol 1986;8:126-136.
12. Kou WH, Nelson SD, Lynch JJ, et al: Effect of flecainide acetate on prevention of electrical induction of ventricular tachycardia and occurrence of ischemic ventricular fibrillation during the early postmyocardial infarction period: Evaluation in a conscious canine model of sudden death. J Am Coll Cardiol 1987;9:359-365.
13. Lederman SN, Wenger TL, Bolster DE, et al: Effects of flecainide on occlusion and reperfusion arrhythmias in dogs. J Cardiovasc Pharmacol 1989;13:541-546.
14. Nattel S: Experimental evidence for proarrhythmic mechanisms of antiarrhythmic drugs. Cardiovasc Res 1998;37:567-577.
15. Cardiac Arrhythmia Suppression Trial (CAST) Investigators: Special report: Preliminary report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989;321:406-412.
16. IMPACT Research Group: International Mexiletine and Placebo Antiarrhythmic Coronary Trial: I. Report on arrhythmia and other findings. J Am Coll Cardiol 1984;4:1148-1163.
17. Greenberg HM, Dwyer EM, Hochman JS, et al: Interaction of ischaemia and encainide/flecamide treatment: A proposed mechanism for the increased mortality in CAST I. Br Heart J 1995;74:631-635.
18. Katz AM: Calcium channel diversity in the cardiovascular system. J Am Coll Cardiol 1996;28:522-529.
19. ++ channels and pharmacological blockade: Potential pathophysiological relevance. Cardiovasc Drugs Ther 1997;11:723-739.
20. Fareh S, Thibault B, Nattel S: Treatment with a T-type calcium channel blocker prevents atrial fibrillation caused by tachycardia-induced atrial remodeling. (Abstract) Circulation 1998;98(Suppl I):I-210.
21. Courtemanche M, Ramirez RJ, Nattel S: Ionic mechanisms underlying human atrial action potential properties: Insights from a mathematical model. Am J Physiol 1998;275:H301-H321.
22. Courtemanche M, Ramirez R, Nattel S: Ionic targets for drug therapy and AF-induced electrical remodeling: Insights from a human atrial action potential model. (Abstract) PACE 1998;21(Pt II):899.
23. Ackerman MJ, Clapham DE: Cardiac chloride channels. Trends Cardiovasc Med 1993;3:23-28.
24. Hume JR, Harvey RD: Chloride conductance pathways in heart. Am J Physiol 1991;261(Pt 1):C399-C412.
25. Faivre JF, Bril A: The cardiac chloride channels as molecular targets for antiarrhythmic therapy. Pharmacol Rev Commun 1997;9:61-70.
26. Colatsky TJ, Follmer CH, Starmer CF: Channel specificity in antiarrhythmic drug action: Mechanism of potassium channel block and its role in suppressing and aggravating cardiac arrhythmias. Circulation 1990;82: 2235-2242.
27. Nattel S, Talajic M, Fermini B, et al: Amiodarone: Pharmacology, clinical actions, and relationships between them. J Cardiovasc Electrophysiol 1992;3:266-280.
28. Duan D, Fermini B, Nattel S: Potassium channel blocking properties of propafenone in rabbit atrial myocytes. J Pharmacol Exp Ther 1993;264:1113-1123.
29. Wang Z, Fermini B, Nattel S: Effects of flecainide, quinidine, and 4-aminopyridine on transient outward and ultrarapid delayed rectifier currents in human atrial myocytes. J Pharmacol Exp Ther 1995;272:184-196.
30. Salata JJ, Brooks RR: Pharmacology of azimilide dihydrochloride (NE-10064), a class III antiarrhythmic agent. Cardiovasc Drug Rev 1997;15:137-156.
31. + current acting as pure class III antiarrhythmic agents. J Cardiovasc Pharmacol 1992; 20(Suppl 2):S106-S113.
32. K1 blockade: A new antiarrhythmic mechanism: Effect of RP 58866 on ventricular arrhythmias in rat, rabbit, and primate. Circulation 1993;87:1979-1989.
33. Kr. Circulation 1996;94:2938-2946.
34. + current, by the diuretic agent indapamide in guinea pig myocytes. Circ Res 1994;75:879-886.
35. +, transient outward, and delayed rectifier currents in canine atrial myocytes. Circ Res 1998;83:158-166.
36. Guerra PG, Talajic M, Roy D, et al: Is there a future for antiarrhythmic drug therapy? Drugs 1998;56:761-781.
37. Lazzara R: From first class to third class: Recent upheaval in antiarrhythmic therapy - lessons from clinical trials. Am J Cardiol 1996;78:28-33.
38. Hondeghem LM, Snyders DJ: Class III antiarrhythmic agents have a lot of potential but a long way to go: Reduced effectiveness and dangers of reverse use dependence. Circulation 1990;81:686-690.
39. Wang J, Bourne GW, Wang Z, et al: Comparative mechanisms of antiarrhythmic drug action in experimental atrial fibrillation: The importance of use-dependent effects on refractoriness. Circulation 1993;88: 1030-1044.
40. Wang J, Feng J, Nattel S: Class III antiarrhythmic drug action in experimental atrial fibrillation: Differences in reverse use dependence and effectiveness between dsotalol and the new antiarrhythmic drug ambasilide. Circulation 1994;90:2032-2040.
41. Nattel S, Liu L, St-Georges D: Effects of the novel antiarrhythmic agent azimilide on experimental atrial fibrillation and atrial electrophysiologic properties. Cardiovasc Res 1998;37:627-635.
42. + current, on repolarization in human and guinea pig ventricular myocytes. Cardiovasc Res 1998;38:441-450.
43. + current in guinea pig ventricular cells. J Pharmacol Exp Ther 1992;262:99-108.
44. + current through a nifedipine inhibited inward channel. J Pharmacol Exp Ther 1998;286:9-22.
45. Kr) in AT-1 cells: Concentration-, time-, voltage-, and use- dependent effects. Circulation 1995;91:1799-1806.
46. Wijffels MC, Kirchhof CJ, Dorland R, et al: Atrial fibrillation begets atrial fibrillation: A study in awake chronically instrumented goats. Circulation 1995;92: 1954-1968.
47. Yue L, Feng J, Gaspo R, et al: Ionic remodeling underlying action potential changes in a canine model of atrial fibrillation. Circ Res 1997;81:512-525.
48. Garratt C, Dorland R, Duytschaever M, et al: The lower success rate of pharmacological cardioversion of atrial fibrillation of longer duration is due to atrial remodeling. (Abstract) PACE 1997;20(Pt II): 1154.
49. Le Grand BL, Hatem S, Deroubaix E, et al: Depressed transient outward and calcium currents in dilated human atria. Cardiovasc Res 1994;28:548-556.
50. Kääb S, Nuss HB, Chiamvimonvat N, et al: Ionic mechanism of action potential prolongation in ventricular myocytes from dogs with pacing-induced heart failure. Circ Res 1996;78:262-273.
51. ++-dependent outward currents in myocytes from epicardial border zone of 5-day infarcted canine heart. Am J Physiol 1997;273: H1386-H1394.
52. + currents in myocytes from epicardial border zone of the infarcted heart: A possible ionic mechanism for reduced excitability and postrepolarization refractoriness. Circ Res 1997;81: 110-119.
53. Fozzard HA, Hanck DA: Structure and function of voltage-dependent sodium channels: Comparison of brain II and cardiac isoforms. Physiol Rev 1996;76: 887-926.
54. Roden DM, George AL: Structure and function of cardiac sodium and potassium channels. Am J Physiol 1997;273(Pt2):H511-H525.
55. Mori Y, Mikala G, Varadi G, et al: Molecular pharmacology of voltage-dependent calcium channels. Jpn J Pharmacol 1996;72:83-109.
56. Barry DM, Nerbonne JM: Myocardial potassium channels: Electrophysiological and molecular diversity. Annu Rev Physiol 1996;58:363-394.
57. Clapham DE: The list of potential volume-sensitive chloride currents continues to swell (and shrink). J Gen Physiol 1998;111:623-624.
58. + channel subtypes. Biophys J 1996;70:1700-1708.
59. + channels by local anesthetics. Science 1994;265:1724-1728.
60. + channels. Circ Res 1998;82:386-395.
61. + channel: Role of S6 in antiarrhythmic drug binding. Circ Res 1996;78:1105-1114.
62. + current in cultured adult human atrial myocytes. Circ Res 1997;80:572-579.
63. Loussouarn G, Charpentier F, Mohammad-Panah R, et al: KvLQT1 potassium channel but not IsK is the molecular target for trans-6-cyano-4(N-ethylsulfonyl-N-methylamino)-3-hydroxy-2,2-dimethyl-chromane. Mol Pharmacol 1997;52:1131-1136.
64. Zipes DP: The long QT syndrome: A Rosetta stone for sympathetic related ventricular tachyarrhythmias. Circulation 1991;84:1414-1419.
65. Takumi T, Ohkubo H, Nakanishi S: Cloning of a membrane protein that induces a slow voltage-gated potassium current. Science 1988;242:1042-1045.
66. Kr potassium channel. Cell 1995;81:299-307.
67. Ks cardiac potassium current. Nature 1996;384:78-80.
68. Ks potassium channel. Nature 1996;384:80-83.
69. Ackerman MJ: The long QT syndrome: Ion channel diseases of the heart. Mayo Clin Proc 1998:73:250-269.
70. Bennett PB, Yazawa K, Makita N, et al: Molecular mechanism for an inherited arrhythmia. Nature 1995;376:683-685.
71. + channel-linked long-QT syndrome. Circ Res 1996;78:916-924.
72. + channels. Circ Res 1996; 79:103-108.
73. Wang DW, Yazawa K, Makita N, et al: Pharmacological targeting of long QT mutant sodium channels. J Clin Invest 1997;99:1714-1720.
74. + channel blockade and to increases in heart rate: Implications for gene-specific therapy. Circulation 1995;92:3381-3386.
75. Compton SJ, Lux RL, Ramsey MR, et al: Genetically defined therapy of inherited long-QT syndrome: Correction of abnormal repolarization by potassium. Circulation 1996;94:1018-1022.